Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Dermatology Immune Disorders Neurology

UCB CEO Doliveux pledges to provide clear path for his successor

This article was originally published in Scrip

Executive Summary

With the clock ticking down to his retirement, UCB CEO Roch Doliveux revealed two pledges he is making to his successor Jean-Christophe Tellier who is due to take over the reins 1 January 2014. He has promised not to be a "mother-in-law" providing unwanted advice and looking over Mr Tellier's shoulder but has pledged over the next 10 months to continue developing the business to allow him to be more successful.

Table

View full table

Topics

Related Companies

Tags:
Dermatology Immune Disorders Neurology
Latest Headlines

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

See All
UsernamePublicRestriction

Register

SC024600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By